Immatics Biotechnologies GmbH

Clinical trials sponsored by Immatics Biotechnologies GmbH, explained in plain language.

Immatics Biotechnologies GmbH IMTX NASDAQ

A biopharmaceutical company developing T-cell receptor-based immunotherapies for cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug IMA402 targets tough cancers in early trial Results expected Sep 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1

New drug IMA402 targets tough cancers in early trial

Disease control Recruiting now

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

Phase 1/2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Immatics Biotechnologies GmbH

Upcoming readouts

New drug IMA402 targets tough cancers in early trial